Ovarian Cancer Clinical Trials in Chicago

Showing 101-120 of 122 trials

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00066456

Phase I trial to study the effectiveness of low-dose radiation therapy to the abdomen combined with docetaxel in treating patients who have recurrent or persistent advanced ovarian, peritoneal, or fallopian tube cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells.

Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian Carcinoma+2 more

Gynecologic Oncology Group13 participantsStarted Sep 2003

Chicago, Illinois, United States • Indianapolis, Indiana, United States • Iowa City, Iowa, United States +4 more locations

WITHDRAWNPHASE1/PHASE22.2 miles

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

NCT01624493

This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.

Ovarian Cancer

Hoosier Cancer Research NetworkStarted Oct 2012

Chicago, Illinois, United States • Indianapolis, Indiana, United States • Sydney, New South Wales, Australia +3 more locations

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Ovarian Cancer Trials in Other Cities

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer

ABT-751 in Treating Young Patients With Refractory Solid Tumors

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

Ovarian Cancer Vaccine for Patients in Remission

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Other Conditions in Chicago